Ligand Pharmaceuticals Inc (NASDAQ:LGND)
| 125.21 Delayed Data As of 3:59pm ET |  -5.32 / -4.08%Today’s Change | 78.26 Today|||52-Week Range 219.75 | +25.90% Year-to-Date |
Latest LGND News | Press Releases
| Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales May 04 / Zacks.com - Paid Partner Content | Ligand Pharmaceuticals Inc (LGND) Q1 2021 Earnings Call Transcript May 04 / MotleyFool.com - Paid Partner Content |
| Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug May 04 / MotleyFool.com - Paid Partner Content | Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates May 03 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 130.53 |
| Today’s open | 122.74 |
| Day’s range | 125.21 - 129.46 |
| Volume | 8,273 |
| Average volume (3 months) | 461,222 |
| Market cap | $2.2B |
Data as of 3:59pm ET, 05/12/2021
Growth & Valuation
| Earnings growth (last year) | -100.56% |
| Earnings growth (this year) | +35.19% |
| Earnings growth (next 5 years) | +20.00% |
| Revenue growth (last year) | +54.98% |
| P/E ratio | 53.7 |
| Price/Sales | 8.63 |
| Price/Book | 2.99 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MDGLMadrigal Pharmaceuti... | +0.59 | +0.44% |
| ---- | ||
| ---- | ||
| OPKOPKO Health Inc | -0.09 | -2.78% |
Data as of 4:00pm ET, 05/12/2021
Financials
| Next reporting date | August 9, 2021 |
| EPS forecast (this quarter) | $1.34 |
| Annual revenue (last year) | $186.4M |
| Annual profit (last year) | -$3.0M |
| Net profit margin | -1.60% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
